CLGN (CollPlant Biotechnologies) ROCE %: -167.77% (As of Mar. 2026)

What is CollPlant Biotechnologies ROCE %?

CollPlant Biotechnologies CLGN -2.46% 35 ROCE % is -167.77% as of Mar. 2026. GuruFocus rates CLGN with a GF Score™ of 35/100 and a GF Value™ of $0.29 (Modestly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CollPlant Biotechnologies's annualized ROCE % for the quarter that ended in Mar. 2026 was -167.77%.

CollPlant Biotechnologies (NAS:CLGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CollPlant Biotechnologies ROCE % Related Terms

CollPlant Biotechnologies ROCE % Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies ROCE % Chart

CollPlant Biotechnologies Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

0.23

-41.26

-22.92

-74.01

-96.28

CollPlant Biotechnologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-43.59	-87.06	-107.28	-128.77	-167.77

35GF Score

CollPlant Biotechnologies Ltd CLGN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CollPlant Biotechnologies ROCE % Calculation

CollPlant Biotechnologies's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-11.483	/	( ( (18.71 - 2.97)	+	(10.785 - 2.672) )	/ 2 )
	=	-11.483	/	( (15.74	+	8.113)	/ 2 )
	=	-11.483	/	11.9265
	=	-96.28 %

CollPlant Biotechnologies's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-12.46	/	( ( (10.785 - 2.672)	+	(9.183 - 2.442) )	/ 2 )
	=	-12.46	/	( ( 8.113	+	6.741 )	/ 2 )
	=	-12.46	/	7.427
	=	-167.77 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -167.77% mean?

CollPlant Biotechnologies (CLGN) has a ROCE % of -167.77% as of Mar. 2026.

Is CollPlant Biotechnologies' ROCE % too high?

CollPlant Biotechnologies' current ROCE % is -167.77%. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does CollPlant Biotechnologies' ROCE % compare to CPMV and TCRT?

CollPlant Biotechnologies' ROCE % of -167.77% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. CollPlant Biotechnologies's current ROCE % is -167.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CollPlant Biotechnologies stock overvalued right now?

Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.34 — trading 17.3% above its estimated fair value. The current ROCE % is -167.77%. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current ROCE % is -167.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of $0.34 is trading 17.3% above its estimated GF Value™ of $0.29. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for CLGN:

ROCE %: -167.77%
GF Value™: $0.29 vs. price of $0.34 (17.3% above fair value)
GF Score™: 35/100 with 4 warning signs

No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Industry Healthcare Biotechnology

Comparable Companies CPMV TCRT DRMA ENSC MBIO RNAZ ELAB ALZN PCSA CELZ VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CPT:Germany

Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.

35GF Score

Get the complete analysis for CLGN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34

Price

$0.29

GF Value

View CLGN Analysis

See ROCE % data for all stocks →